Business Insider

Dr Reddy’s Laboratories (RDY) Gets a Buy from Barclays

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report), with a price target of $17.00. The company’s shares closed yesterday ...
Business Wire

Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination ...

Under the Agreement, Dr. Reddy’s will obtain commercialization rights for COYA 302 in the United States, Canada, the European Union and the United Kingdom, for patients with ALS COYA will be ...
Nasdaq

India's Dr Reddy's Labs profit jumps 12% on strong U.S. sales

Generic drugmaker Dr Reddy's Laboratories Ltd reported a 12.2% rise in second-quarter profit on Friday, helped by the launch of the generic version of a popular cancer drug in its key North American ...
Business Insider

Barclays Reaffirms Their Buy Rating on Dr Reddy’s Laboratories (RDY)

Barclays analyst Balaji Prasad maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report) today and set a price target of $17.00. The company’s shares closed last Friday at $14.01.
Business Wire

Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its ...